Treatment planning for patients with low rectal cancer in a multicenter prospective organ preservation study
•Multicenter trial with high dose radiotherapy treatment plans to low rectal cancer.•Non-surgical management of rectal cancer with definitive high dose radiotherapy.•Intercenter differences in doses to organs at risk.•Tumor boost to 62 Gy: less than 5 % of patients receive more than 60 Gy to main OA...
Gespeichert in:
Veröffentlicht in: | Physica medica 2024-02, Vol.118, p.103206-103206, Article 103206 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Multicenter trial with high dose radiotherapy treatment plans to low rectal cancer.•Non-surgical management of rectal cancer with definitive high dose radiotherapy.•Intercenter differences in doses to organs at risk.•Tumor boost to 62 Gy: less than 5 % of patients receive more than 60 Gy to main OARs.•Proposed treatment planning goals may be used for future rectal cancer radiotherapy.
Non-surgical management of rectal cancer relies on (chemo)radiotherapy as the definitive treatment modality. This study reports and evaluates the clinical high dose radiotherapy treatment plans delivered to patients with low resectable rectal cancer in a Danish multicenter trial.
The Danish prospective multicenter phase II Watchful Waiting 2 trial (NCT02438839) investigated definitive chemoradiation for non-surgical management of low rectal cancer. Three Danish centers participated in the trial and committed to protocol-specified treatment planning and delivery requirements. The protocol specified a dose of 50.4 Gy in 28 fractions to the elective volume (CTV-/PTV-E) and a concomitant boost of 62 Gy in 28 fractions to the primary target volume (CTV-/PTV-T).
The trial included 108 patients, of which 106 treatment plans were available for retrospective analysis. Dose coverage planning goals for the main target structures were fulfilled for 94% of the treatment plans. However, large intercenter differences in doses to organs-at-risk (OARs) were seen, especially for the intestines. Five patients had a V60Gy>10 cm3 for the intestines and two patients for the bladder.
Prescribed planning goals for target coverage were fulfilled for 94% of the treatment plans, however analysis of OAR doses and volumes indicated intercenter variations. Dose escalation to 62 Gy (as a concomitant boost to the primary tumor) introduced no substantial high dose volumes (>60 Gy) to the bladder and intestines. The treatment planning goals may be used for future prospective evaluation of highdose radiotherapy for organ preservation for low rectal cancer. |
---|---|
ISSN: | 1120-1797 1724-191X |
DOI: | 10.1016/j.ejmp.2023.103206 |